$MEDS

DataMeds AI, Inc.

DataMeds AI is a holding company for businesses in pharmaceuticals and healthcare services. Its operations include Wellgistics Pharmacy, which provides general and specialty pharmacy services, fills prescriptions and delivers medications to patients, and Wellgistics LLC, a pharmaceutical wholesaler and third-party logistics provider serving manufacturers and independent pharmacies. The company also operates DelivMeds, a technology platform that facilitates prescription transfers, pharmacy routing, patient support and clinical services through digital tools. Wellgistics Pharmacy makes money through prescription fulfillment and reimbursement from payors and patient copayments. Wellgistics LLC provides pharmaceutical distribution and logistics services to manufacturers and pharmacies. DelivMeds offers hub, clinical and data services, with its stated model involving fees from manufacturers and other channel partners. The company’s main office is in Tampa, Florida; Wellgistics Pharmacy is also located there.

4
5
1

No SEC Form 4 filings for $MEDS in the last 30 days.

See all $MEDS insider activity →

DataMeds AI, Inc. (MEDS): Entry into a Material Definitive Agreement

DataMeds AI, Inc. (MEDS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On November 16, 2026, DataMEDS AI, Inc. (the “Company”) entered into an ATM sales agreement (the “Sales Agreement”) with Dawson James Securities, Inc. (the “Sales Agent”), pursuant to which the Company may offer and sell, from

MEDS sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 10 news stories mentioning MEDS (DataMeds AI, Inc.). Coverage has skewed bullish: 4 bullish, 5 neutral, and 1 bearish.

Recent MEDS coverage spans corporate actions, earnings and financial news.

What's driving MEDS

AlphAI scores every news story that mentions MEDS with an AI model for sentiment and relevance, and aggregates insider trades from DataMeds AI, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $MEDS

Score
$MEDSMedOffering· $0.0001

DataMeds AI, Inc. (MEDS): Entry into a Material Definitive Agreement

DataMeds AI, Inc. (MEDS) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On November 16, 2026, DataMEDS AI, Inc. (the “Company”) entered into an ATM sales agreement (the “Sales Agreement”) with Dawson James Securities, Inc. (the “Sales Agent”), pursuant to which the Company may offer and sell, from

$MEDSMedEarnings

DataMEDS AI Reports 50% Sequential Revenue Growth in Third Quarter 2026 From Second Quarter 2026, Delivers Net Profit Per Share of $2.72 and Provides…

DataMeds AI, Inc. (MEDS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE DataMEDS AI Reports 50% Sequential Revenue Growth in Third Quarter 2026 From Second Quarter 2026, Delivers Net Profit Per Share of $2.72 and Provides Business Update ■ Third quarter 2026 revenue of $2.7 million, up 50% from $1.8 million in the s

DataMeds subsidiary completes first peptide sale under FDA policy

DataMeds AI (NASDAQ:MEDS) announced its Corexa Pharmacy subsidiary completed its first sale of six peptides recommended by the FDA. The peptides are not FDA-approved. The company plans to develop a pricing model and market to prescribing physicians. The U.S. compounding pharmacy market is projected to grow to $31.77 billion by 2034, according to Precedence Research.

$MEDSMedM&A· acquirer · terminated

DataMeds AI, Inc. (MEDS): Termination of a Material Definitive Agreement

DataMeds AI, Inc. (MEDS) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. Exhibit 99.1 DataMEDS AI Announces Termination of Second Amended and Restated Letter of Intent TAMPA, FL / ACCESS Newswire / November 3, 2026 / DataMeds AI, Inc . (“DataMeds SI,” “DataMEDS” or the “Company”) (NASDAQ:MEDS), a healthcare company that integrates its health informati

A Florida health plan expects 25,000–30,000 members in 2027; an app is proposed for obesity and diabetes care

DataMeds AI (NASDAQ:MEDS) signed a non-binding MOU with a Florida HMO to deploy its Health Lives Here app, targeting 25,000–30,000 members in 2027. The app aims to improve medication adherence and health outcomes for obesity and diabetes patients. Revenue will be generated on a per-member-per-month basis, with potential additional income from related services. Definitive agreements are expected in Q4 2026, with rollout in Q1 2027.

Related tickers